Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder: A Double-Blind, Placebo-Controlled Trial.

CONCLUSIONS: Continuation-phase escitalopram delayed time to relapse, and fewer escitalopram-treated subjects relapsed than did placebo-treated subjects. Body dysmorphic disorder severity significantly improved during 6 additional months of escitalopram treatment following acute response; more than one-third of escitalopram-treated subjects experienced further improvement. PMID: 27056606 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/27056606?dopt=Abstract

Source: The American Journal of Psychiatry - April 7, 2016 Category: Psychiatry Authors: Phillips KA, Keshaviah A, Dougherty DD, Stout RL, Menard W, Wilhelm S Tags: Am J Psychiatry Source Type: research